Quarterly report · Q2
4886.TEDINET S100PIUD
Period2022-04-01 → 2022-09-30
Filed2022-11-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥30.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥56.6bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥28.5bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥2.9bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥2.7bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥4.9bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.7bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥4.1bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.3bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥2.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥2.3bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | −¥2.8bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥86.2bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥83.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥78.3bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.2bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥34.4bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥52.0bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥48.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥41.8bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥17.2bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥12.1bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.2bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥17.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥199m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥6.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥427m | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.3bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥83.18 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥36.25 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-98.52 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-137.17 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 60.3% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.7% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.4% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 34
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2022-09-30 | ¥114m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2022-09-30 | ¥86m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2022-09-30 | −¥20m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥28m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥28m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥473m |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥231m |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥26.9bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥26.9bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥30.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥30.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥3.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2021-09-30 | ¥93m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2021-09-30 | ¥66m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥26m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2021-09-30 | −¥26m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥26m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥26m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥342m |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E35791-000Animal Health Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥229m |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥25.6bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥25.6bn |
| jpcrp040300-q2r_E35791-000Pharmaceutical Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-09-30 | ¥28.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-09-30 | ¥28.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥26m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-09-30 | ¥3.0bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 470
| Item | Context | Value | Unit |
|---|---|---|---|
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 30200000000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -28000000 | JPY |
| Net sales | CurrentYTDDuration | 30172000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E35791-000PharmaceuticalBusinessReportableSegmentsMember | 3141000000 | JPY |
| Operating income | CurrentYTDDuration_jpcrp040300-q2r_E35791-000AnimalHealthBusinessReportableSegmentsMember | 231000000 | JPY |
| Operating income | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | -20000000 | JPY |
| Operating income | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 3352000000 | JPY |
| Operating income | CurrentYTDDuration_ReconcilingItemsMember | -473000000 | JPY |
| Operating income | CurrentYTDDuration | 2879000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)四半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の４の７第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2022-11-10 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第２期第２四半期（自 2022年７月１日 至 2022年９月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)あすか製薬ホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | ASKA Pharmaceutical Holdings Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 山口 隆 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都港区芝浦二丁目５番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)（03）5484－8845（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)グループ経理部長 市川 学 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都港区芝浦二丁目５番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)（03）5484－8845（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)グループ経理部長 市川 学 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E35791 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 48860 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)あすか製薬ホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | ASKA Pharmaceutical Holdings Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2022-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2021-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |